Biomarkers to identify individuals at risk for progression of s. Japonicum associated hepatic fibrosis with point of care test development
Active Cooperative Agreement Awarded Last action
- Award ID
- U01AI168560
- Recipient
-
Rhode Island Hospital UEI N876TLXYGCG4 Part of Lifespan Corp
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,299,023
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 75% complete
- Originally
- Funding
-
- $4,667,022.00 Federal
- $632,001.00 Non-federal
- Place of performance
- Providence, RI 02903, USA
Award details come from USAspending.gov.
Description
- Abstract
- The overall goals of this tropical medicine research center (tmrc), proposed for the research institute of tropical medicine (ritm) in the philippines, are to a) execute the key scientific aims of this study, b) build research capacity at ritm, and c) build research capacity and support the development of junior investigators at all tmrcs in partnership with the tmrc coordinating center's "opportunity funds" and other initiatives currently, preventative chemotherapy strategies with praziquantel (PZQ) are the mainstay of treatment for schistosomiasis, with "mass drug administration" (MDA) delivered annually or BI-annually. The primary cause of severe morbidity and death due to intestinal schistosomiasis is portal fibrosis secondary to intra-hepatic EGG deposition with consequent portal hypertension and esophageal varices with high risk of hemorrhage. Importantly, there are no current recommendations to identify and more aggressively treat individuals with hepatic fibrosis in most regions, including the philippines, leaving individuals to receive infrequent, if any, treatment. Currently, little is known with respect to risk factors for progression to higher grade portal fibrosis, including biomarkers to identify risk. This is a lost opportunity to mitigate this risk through more frequent treatment, which has been shown to halt and even reverse fibrosis if identified early. Our groups have developed a multiplexed "fibroplex_V2" assay that now captures 38 key analytes involved in fibro-proliferation or degradation. We will employ this to address the scientific goals of the study which are to: 1) evaluate biomarkers that will identify individuals with s. Japonicum associated hepatic fibrosis as diagnosed by ultrasound (US) at baseline as well as biomarkers that identify risk of progression from mild-moderate to higher grades as assessed by US annually for three years 2) to develop diagnostic tests to facilitate identification of high-risk individuals in the field who would ultimately benefit from more frequent treatment with PZQ or other treatment approaches. We expect many analytes will predict progression and these will be developed singly or in combination as lateral flow-based assays that can ultimately be developed as pocts for use with MDA. The availability of potential treatment approaches to halt progression, the lack of approaches to reverse higher grade periportal fibrosis once established, and sub-optimal interventions for addressing portal hypertension and its high mortality rate once established, make this an ideal screening target. Biomarkers that longitudinally predict risk of progression to less reversible grades are a crucial first step. The successful execution of these aims will also build research capacity at ritm and provide outstanding opportunities for related studies through tmrc "opportunity funds" as well as future grants to evaluate different treatment strategies for individuals at risk for fibrosis progression with definitive randomized controlled trials.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $340,240 | $0 | |
| Amendment | $295,657 | $0 | |
| Amendment | $295,657 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $601,595 | $0 | |
| Amendment | $618,935 | $0 | |
| Amendment | $618,935 | $0 | |
| Amendment | $632,001 | $0 | |
| Amendment | $632,001 | $632,001 | |
| Original award | $632,001 | $0 |
Show all 12
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Brown University | $60,504 | |
| Research Institute For Tropical Medicine | $33,822 | |
| Brown University | $46,365 |
Quick answers
Who received award U01AI168560?
U01AI168560 was awarded to Rhode Island Hospital by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2022.
How much is award U01AI168560 worth?
$5,299,023 has been obligated on U01AI168560: $4,667,022 in federal funding and $632,001 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award